Physician profile
Troy Millican
NPI 1205846573
$1,917.23
in general payments reported to CMS, 2019-2025
25 companies · $379 in 2025
The $379 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $208 · 2021: $44.20 · 2022: $118 · 2023: $382 · 2024: $786 · 2025: $379.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,547.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,546.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $558.77 | 2021-2025 | |
| Glaxosmithkline, LLC. | $156.85 | 2023-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abiomed | $154.90 | 2024-2025 | Impella |
| Astrazeneca Pharmaceuticals LP | $145.01 | 2023-2025 | Farxiga, Breztri, Airsupra |
| Lilly USA, LLC | $114.57 | 2019 | |
| Exact Sciences Corporation | $92.72 | 2023-2025 | Cologuard Collection Kit |
| Genzyme Corporation | $78.27 | 2024 | |
| Dexcom, INC. | $68.91 | 2024 | Dexcom G6 Transmitter |
| Amgen INC. | $66.11 | 2024-2025 | Evenity, Prolia |
| Edwards Lifesciences Corporation | $59.53 | 2023 | |
| Regeneron Healthcare Solutions, INC. | $53.49 | 2024 | Dupixent |
| Insmed, INC. | $52.22 | 2024-2025 | Arikayce |
| Viatris Specialty LLC | $50.17 | 2025 | Yupelri |
| Merck Sharp & Dohme LLC | $42.82 | 2024 | Gardasil 9, Gardasil, Vaxneuvance |
| Supernus Pharmaceuticals, INC. | $35.07 | 2019 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $30.57 | 2019 | |
| Tactile Systems Technology INC | $28.09 | 2024 | Flexitouch Plus, Entre Plus |
| Ethicon US, LLC | $21.03 | 2024 | Vistaseal, Stratafix, Dermabond |
| Inogen, INC. | $17.01 | 2025 | |
| Pfizer INC. | $16.52 | 2023 | |
| Janssen Pharmaceuticals, INC | $16.12 | 2023 | Xarelto |
| Astellas Pharma US INC | $15.24 | 2024 | Veozah |
| Vital Connect, INC | $15.21 | 2025 | Vitalpatch Rtm |
| Allergan, INC. | $14.80 | 2019 | |
| Novo Nordisk INC | $13.23 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Troy Millican listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.